LYRA
Lyra Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
lyra therapeutics, inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. the company's xtreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. its product candidates include lyr-210 and lyr-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. the company was formerly known as 480 biomedical, inc. and changed its name to lyra therapeutics, inc. in july 2018. lyra therapeutics, inc. was founded in 2005 and is headquartered in watertown, massachusetts.
Market Cap: 289 Million
Primary Exchange: NASDAQ
Website: lyratherapeutics.com
Shares Outstanding: 52.6 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.892426875360549
Sector: Manufacturing
Industry: Surgical and Medical Instrument Manufacturing
Ethical Flags
Longest drawdown: 1201 trading days
From: 2020-05-04 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|